Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

 Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Shots:

  • Lilly has expanded its ongoing BLAZE-4 trial to assess the administration of bamlanivimab (700mg) with VIR-7831 (500mg) for symptomatic COVID-19 in the outpatient setting. These are two neutralizing Abs that bind to different epitopes of the SARS-CoV-2 spike protein
  • The companies reported the first patient has been dosed in the expanded study
  • Bamlanivimab is authorized for emergency use in the US for mild-to-mod. COVID-19 in high-risk patients. VIR-7831 is being evaluated in the global P-II/III COMET-ICE trial for the early treatment of COVID-19 in adults at high risk of hospitalization

Click here ­to­ read full press release/ article | Ref: GSk | Image: GSk

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post